Get all premium features to the best stock analysis tool

An Axogen executie reported selling 5,221 shares of Common Stock for a transaction value of approximately $171,000 on March 16, 2026. This represented 1.95% of total holdings as reported in the Form 4; direct holdings, meanwhile, declined from 268,002 to 262,781 shares.

DAFNA Capital Management sold 265,456 AXGN shares in the fourth quarter, with an estimated transaction value of $6.53 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $2.36 million, reflecting both trading activity and price movements.

The Fund rebounded and outperformed the Russell 2000 ® Growth Index in the fourth quarter. Boot Barn's revenues and earnings handily exceeded estimates, with greater transaction volumes and new store openings. Abivax reported strong clinical trial results for its obefazimod treatment to address ulcerative colitis in a longer lasting manner.

Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript

Axogen, Inc. (AXGN) reported strong 21% revenue growth but missed EPS expectations, prompting an 8% share decline and highlighting near-term margin pressures. AXGN is transitioning to a regulated biologics platform with Avance FDA approval, aiming for sustainable growth, 18%+ revenue guidance, and positive free cash flow in 2026. Gross margin compression is driven by one-time regulatory costs and biologics conversion, expected to normalize as biologics pricing and payer coverage expand.

Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript

AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.08 per share a year ago.